MustGrow Announces 2025 Financial Results Ready to Announce with Confidence?

Investor Webcast: Thursday, April 30 th at 4:00pm ET / 1:00pm PT

Please join/register at least 5 minutes prior to the call.

Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.

Saskatoon, Saskatchewan--(Newsfile Corp. - April 29, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, announces its audited financial results for the year ended December 31, 2025. For complete details, please refer to the Audited 2025 Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.

Key Highlights for 2025:

"Throughout 2025, management focused on securing capital and increasing third-party manufacturing capacity to prepare for growing TerraSante TM demand in the U.S," stated Corey Giasson, President and CEO of MustGrow. "Closing down our NexusBioAg Canadian sales division to allocate more capital and resources to TerraSante TM production was a key strategic decision we made in 2026. TerraSante TM sales were up 377% in 2025 versus 2024, as demand from U.S. retailers and farmers outstripped our inventory supply. For 2026, we anticipate continued growth in TerraSante TM sales and an improvement in gross margins with more favourable U.S. tariffs and as we shift from small scale batch production to continuous production with our contract manufacturers. In addition, we are not only focused on meeting accelerating U.S. sales growth, but also look to commercialize TerraSante TM in new countries where there exists a need and potential for fast tracked registrations."

Notes:

1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.

About MustGrow

MustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSante TM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 110 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.

For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson Director & CEO

Phone: +1-306-668-2652

info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about:, the future demand for the Company's products, future sales and margins from those sales, and the impact of any tariffs,and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294798

Source: MustGrow Biologics Corp.

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for MustGrow Biologics Corp. or all companies in the Cannabis Breeder, Agriculture, Biotechnology, Cannabis industry.

MustGrow Announces 2025 Financial Results

2026-04-29 5:00 PM EDT

MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product

2026-04-28 7:00 AM EDT

MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root Systems

2026-02-03 10:37 AM EST

Apr 23, 2026

Disclosure Intelligence Series How disclosure works in modern capital markets Most companies treat a U.S. stock exchange listing as a structural milestone. In practice, it represents something more significant. Entering U.S. markets is not just a listing event. It is a fundamental shift in how a company’s information is communicated, interpreted, and acted on. As of March 2026, 187 TSX and TSX Venture issuers are interlisted on U.S. exchanges, within a broader group of 258 interlisted...

Economy, Business and Finance

Agriculture

Biotechnology

Chemicals

Cannabis Breeder

Agriculture

Biotechnology

Cannabis